Liver fibrosis attributed to lipid lowering medications: two cases

Authors


Dr Ooi Division of Endocrinology and Metabolism, The Ottawa Hospital – Civic Campus, 1053 Carling Avenue, Ottawa, Ontario, Canada, K1Y 4E9 (Fax: 613 761-5316; e-mail: tcooi@ottawahospital.on.ca).

Abstract

Abstract. Punthakee Z, Scully LJ, Guindi MM, Ooi TC (Department of Medicine, Division of Gastroenterology, Department of Pathology and the Laboratory of Medicine and the Division of Endocrinology and Metabolism, The Ottawa Hospital – Civic Campus, University of Ottawa, Ottawa, Canada). Liver fibrosis attributed to lipid lowering medications: two cases (Case Report). J Intern Med 2001; 250: 249–254.

We identified two cases of chronic active hepatitis with liver fibrosis induced by lipid lowering drugs of the statin and fibrate classes despite regular monitoring of transaminases. There are few reports of clinically significant hepatitis induced by these drugs and even fewer cases of fibrosis. Given the growing use of these drugs, there are implications for monitoring patients on long-term therapy for liver damage.

Ancillary